公开(公告)号：US11129807B2

公开(公告)日：2021-09-28

申请号：US16486257

申请日：2018-02-16

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Seth Hopkins ,  Kenneth Koblan ,  Antony Loebel ,  Ajay Ogirala

IPC: A61K31/381 ,  A61P25/18

Abstract: Provided herein are methods for determining if a compound has potential efficacy for the treatment for a specific symptom domain of schizophrenia, such as for example, the treatment of a negative symptom of schizophrenia. In addition, provided herein are methods of determining the prominent symptom domain of a subject suffering from schizophrenia. Further, provided herein are various methods for the treatment of the negative symptoms, cognitive dysfunction symptoms, or both, associated with schizophrenia comprising administering to a subject a therapeutically or prophylactically effective amount of various compounds.

公开(公告)号：US10815249B2

公开(公告)日：2020-10-27

申请号：US16277443

申请日：2019-02-15

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Andrea Bauer ,  Xiaoxia Chen ,  Shahla Jamzad ,  Robert Joseph Prytko ,  Michael Joseph Sizensky ,  Haitao Zhang

IPC: C07D495/04 ,  A61K9/20 ,  A61K45/06 ,  A61K31/381 ,  A61P25/18 ,  A61P25/00

Abstract: Provided are salts of (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine and various of crystal forms thereof, and compositions, medicaments, pharmaceutically acceptable formulations thereof, and methods of making same. In addition, provided are compounds comprising specific particle size distributions of crystalline (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine HCl and methods of making and modulating the particle size distributions.

公开(公告)号：US10702486B2

公开(公告)日：2020-07-07

申请号：US16408701

申请日：2019-05-10

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Thomas Jerussi ,  Qun Kevin Fang ,  Mark G. Currie

IPC: A61K31/135 ,  C07C211/42

Abstract: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.

公开(公告)号：US20200165200A1

公开(公告)日：2020-05-28

申请号：US16749744

申请日：2020-01-22

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： John R. Snoonian ,  Harold Scott Wilkinson

IPC: C07D207/09

Abstract: The various aspects present inventions provide various crystalline forms of (S)-(−)-amisulpride, (R)-(+)-amisulpride, and solvates thereof and methods of making same. In various aspects, the inventions also provide methods of resolving racemic amisulpride.

公开(公告)号：US10570156B2

公开(公告)日：2020-02-25

申请号：US15818044

申请日：2017-11-20

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： John Emmerson Campbell ,  Philip Wendell Jones ,  Michael Charles Hewitt

IPC: A61K31/437 ,  C07D471/04 ,  C07D519/00 ,  A61K45/06 ,  C07D487/04 ,  A61K31/4375 ,  A61K31/4745 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/5383

Abstract: Provided herein are cyclic nucleotide phosphodiesterase inhibitors of Formula (I) of claim 1, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorder.

公开(公告)号：US10533000B2

公开(公告)日：2020-01-14

申请号：US14122519

申请日：2012-05-25

Applicant: Michele L. R. Heffernan ,  Larry Wendell Hardy ,  Frank Xinhe Wu ,  Lakshmi D. Saraswat

Inventor： Michele L. R. Heffernan ,  Larry Wendell Hardy ,  Frank Xinhe Wu ,  Lakshmi D. Saraswat

IPC: C07D413/10 ,  C07D401/10 ,  C07D401/14 ,  C07D413/14 ,  C07D235/18 ,  C07D413/04 ,  C07D413/06 ,  C07D249/08 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  C07D271/06 ,  C07D271/10

Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.

公开(公告)号：US10428021B2

公开(公告)日：2019-10-01

申请号：US15817760

申请日：2017-11-20

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Liming Shao ,  Fengjiang Wang ,  Scott C. Malcolm ,  Michael C. Hewitt

IPC: A61K31/4035 ,  C07D209/44 ,  C07D209/08 ,  C07D209/52

Abstract: Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided.

公开(公告)号：US09994590B2

公开(公告)日：2018-06-12

申请号：US15298469

申请日：2016-10-20

Applicant: Sunovion Pharamaceuticals Inc.

Inventor： John Emmerson Campbell ,  Philip G. Jones ,  Scott Malcolm

IPC: C07D487/04 ,  C07D519/00 ,  A61K31/4985 ,  A61K31/437 ,  A61K31/4709 ,  C07D471/04 ,  A61K31/4745

CPC classification number: C07D519/00 ,  A61K31/437 ,  A61K31/4709 ,  A61K31/4745 ,  A61K31/4985 ,  C07D471/04 ,  C07D487/04

Abstract: Provided herein are substituted [1,2,4]triazlolo[1,5-α]pyrazine compounds, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorders.

公开(公告)号：US20180118727A1

公开(公告)日：2018-05-03

申请号：US15851836

申请日：2017-12-22

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： John Emmerson CAMPBELL ,  Una CAMPBELL ,  Taleen G. HANANIA ,  Liming SHAO

IPC: C07D409/04 ,  C07D491/048 ,  C07D495/04 ,  C07D405/04 ,  C07D409/14

CPC classification number: C07D409/04 ,  C07D405/04 ,  C07D409/14 ,  C07D491/048 ,  C07D495/04

Abstract: Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

公开(公告)号：US09856274B2

公开(公告)日：2018-01-02

申请号：US14884397

申请日：2015-10-15

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： John Emmerson Campbell ,  Philip Jones ,  Michael Charles Hewitt

IPC: A61K31/4353 ,  C07D487/04 ,  C07D519/00 ,  A61K45/06 ,  C07D471/04 ,  A61K31/4375 ,  A61K31/4745 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/5383

CPC classification number: C07D519/00 ,  A61K31/4375 ,  A61K31/4745 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/5383 ,  A61K45/06 ,  C07D471/04 ,  C07D487/04

Abstract: Provided herein are substituted pyrazolopyridine compounds, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorder.